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Abstract 
Background and aims: We characterized the extent and quality of respiratory sensations and sensory-related smok-
ing cues associated with e-cigarette use among those who failed to quit combustible tobacco cigarette (CTC) use 
with traditional FDA approved medications but succeeded in doing so with e-cigarettes. Further, we sought to under-
stand former smokers’ perceptions about the influence of sensory experience with e-cigarette use on CTC cessation 
outcomes.
Methods: A nonrandom purposive sample of 156 participants recruited in the USA through the Consumer Advo-
cates for Smoke Free Alternatives Association Facebook page completed an online cross-sectional survey to assess 
sensory experiences and smoking cues associated with e-cigarette use. Descriptive statistics were calculated, and the 
ANOVA/Kruskal–Wallis test with post hoc testing and the two-sample t test/Wilcoxon rank-sum test, as appropriate 
based on distribution, were used to assess the association between sample characteristics and sensory experiences 
and cues using investigator constructed questions, the Modified Cigarette Evaluation Questionnaire (mCEQ) and the 
Smoking Cue Appeal Survey (SCAS).
Results: With e-cigarette use, participants reported feeling the vapor in their throats, windpipes, noses, lungs, and 
on their tongues; reductions in nicotine craving; and enjoyment of their e-cigarette, including tasting, smelling, and 
seeing the vapor and touching the device. Women had greater craving reduction than men (p = 0.023). Those who 
began smoking at 13 years of age or younger had more satisfaction and had greater sensory enjoyment than those 
who began smoking at 16–17 years of age (p = 0.015 and p = 0.026, respectively), as well as greater sensory enjoy-
ment than those who began smoking at 14–15 years of age (p = 0.047). There was a significant overall association 
between the number of years a respondent smoked and e-cigarette sensory enjoyment (p = 0.038). Participants 
18–34 years old rated e-cigarettes as being more pleasant compared to 45 + years olds, (p = 0.012). Eighty-four per-
cent of participants reported the sensation of the vapor as important in quitting CTCs, and 91% believed the sensa-
tions accompanying e-cigarette use contributed to their smoking cessation success.
Conclusions: For those who failed to quit previously using approved cessation medications to stop smoking ciga-
rettes, sensory experiences associated with e-cigarette use may help smokers quit smoking.
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Background
Smoking is reinforced by a variety of sensory experiences 
[1], but none of the US FDA approved smoking cessa-
tion medications [2] are specifically designed to address 
the “sensory impact” [3] smokers report as desirable, 
satisfying, and reinforcing to their smoking behavior, 
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such as throat scratch, heat or coolness in the upper and 
lower airways, flavor [4, 5], and various sensations on the 
tongue, nose, throat, windpipe, and chest [3, 6, 7]. Exam-
ining sensory impact as an influencer of cessation out-
comes is critical because, while outcomes improve with 
use of approved cessation medications as compared to no 
treatment, relapse rates among treated smokers are still 
estimated to be as high as 50% one year post quit [8–12]. 
Indeed, cessation outcomes following the use of approved 
cessation medications are modest when considered in the 
context of the extent of morbidity and early mortality 
resulting from smoking. Worldwide tobacco use causes 
an estimated six million deaths annually [13], including 
an estimated 480,000 in the United States [14].
It is concerning and perplexing that none of the US-
approved cessation medications address the sensory 
impacts of smoking. Today, it is well understood that 
in addition to nicotine, CTC smoking is reinforced by a 
variety of sensory experiences [1], suggesting the need 
to address multiple influences in smoking cessation 
efforts. In fact, research suggesting the pairing of nicotine 
replacement and sensory reinforces for CTC cessation 
dates as far back as the seminal work of Cain, Rose and 
colleagues [15, 16]. In 1988, the “airway sensory hypoth-
esis” (ASH) was proposed [17], whose foundation built 
upon research [18, 19] influenced by Cain’s [15], seminal 
work concerning the sensory attributes of cigarette smok-
ing. In addressing smoking addiction beyond the physical 
addiction to nicotine, ASH suggests that research efforts 
regarding CTC cessation should be directed toward ways 
of manipulating airway sensations to influence smoking 
behavior and improve cessation outcomes [17].
In fact, the tobacco industry’s (TI’s) approach to 
ingrain smoking is to both maximize the physical addic-
tion to nicotine and the sensory appeal of smoking. The 
TI has extensive programs of sensory focused research, 
spanning decades and supported by large budgets [20, 
21]. In their laboratories, TI scientists developed a keen 
understanding of how to alter proportions of cigarette 
ingredients to create distinct sensory responses when 
smoked. To further entrench smoking, cigarettes are 
custom-designed through extensive marketing research 
to attract specific populations by delivering distinct sen-
sory features [20]. For example, cigarettes were custom 
designed for women over age 35 who prefer a milder and 
less harsh feel in the respiratory tract and black men who 
prefer stronger airway sensations [20].
The emergence of e-cigarettes, battery-operated 
devices that vaporize a solution consisting of glycerol, 
propylene glycol, distilled water, and flavorings, which 
may or may not contain nicotine, [22] has the poten-
tial to address the sensory impact of CTC as a cessation 
intervention. In fact, research focused on the sensory 
aspects of e-cigarette use is developing [23–26]. The 
e-cigarette user inhales the aerosol, referred to as “vap-
ing,” with e-cigarettes sharing many similarities with 
smoking in the behavioral aspect of their use [27]. Many 
users of e-cigarettes are current or former smokers who 
report using them long-term as an alternative to CTCs, 
to reduce cigarette consumption or quit smoking [28, 29], 
to relieve tobacco withdrawal symptoms [30], and/or to 
continue having a “smoking experience without smoking” 
[31, 32].
The goal of this study was to characterize the extent 
and quality of respiratory sensations and sensory-related 
smoking cues associated with e-cigarettes. Study partici-
pants previously tried non-sensory stimulating approved 
cessation medications to quit combustible tobacco ciga-
rette (CTC) without success but were maintaining ces-
sation with a sensory stimulating e-cigarette. Further, we 
examined the value participants placed on the sensory 
aspects of e-cigarette use to influence cessation out-
comes. To our knowledge, there are no other studies that 
have studied our unique population.
In this study, we sought to characterize the extent and 
quality of respiratory sensations and sensory-related 
smoking cues associated with e-cigarette use among 
a group of former CTC smokers. We also examined 
the value participants placed on the sensory aspects of 
e-cigarette use to influence cessation outcomes. These 
individuals previously failed to quit CTC smoking using 
non-sensory stimulating approved cessation medica-
tions, but successfully quit with e-cigarettes, suggesting 
the potential of e-cigarettes or other interventions that 




Through the posting of an advertisement on the Con-
sumer Advocates for Smoke Free Alternatives Associa-
tion (CASAA) Facebook page at https ://www.faceb ook.
com/CASAA media , a convenience sample (N = 156) 
of adult e-cigarette users was recruited to complete an 
anonymous cross-sectional Web-based survey. Clicking a 
Web-link from the Facebook page allowed potential par-
ticipants to learn about the study with an option to move 
forward to screening, consenting, and answering the sur-
vey. Demographic and smoking history questionnaires 
were all to be completed within the Qualtrics platform, 
an online data collection tool (Qualtrics, LLC). Informed 
consent was obtained from all individual participants 
included in the study.
Eligible participants had quit smoking CTCs for at least 
the last 3 months, were currently using e-cigarettes and 
no other intervention as a smoking cessation aide, and 
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had at least one unsuccessful attempt at smoking ces-
sation using one or more first-line approved cessation 
medications: Varenicline, Buproprion, or nicotine gum, 
inhaler, lozenge, nasal spray, or patch. A $10 electronic 
gift card was offered to participants who completed the 
survey [33].
Measures
The survey included investigator-developed questions 
that elaborated on the presence and quality of sensory 
experiences and cues associated with e-cigarette use and 
the importance of sensory experiences’ influence on ces-
sation outcomes. The survey also included the Modified 
Cigarette Evaluation Questionnaire (mCEQ) [34]. Indi-
viduals responded to each of the mCEQ questions on 
a Likert scale, with 1 = not at all to 7 = extremely. Five 
domain scores were created by summing the appropriate 
domain-specific items based on prior confirmatory fac-
tor analysis [34]. The five domains of the 11-item mCEQ 
included Smoking Satisfaction (adapted to Vaping Satis-
faction), Psychological Reward, Enjoyment of Respiratory 
Tract Sensation, Craving Reduction, and Aversion.
In addition, the survey included the Smoking Cue 
Appeal Survey (SCAS), a measure of the sensory cue 
appeal of smoking [35] for which reliability and valid-
ity have also been established. Each item is rated using a 
Likert-scale ranging from 3 (extremely unpleasant) to − 3 
(extremely pleasant) assessing the sight, smell, taste, and 
tactile sensation of e-cigarette use [35]. The SCAS total 
score was calculated by summing all item scores.
We note that the mCEQ and the SCAS have been 
primarily used to evaluate respiratory sensations and 
sensory cues of CTC smokers, but were used here to 
examine those related to e-cigarette use. Therefore, the 
measures were adapted to refer to e-cigarettes and e-cig-
arette use. Demographic and smoking history questions 
were used to describe the sample. All data were de-iden-
tified and collected on July 13, 2017.
Statistical analysis
Descriptive statistics (i.e., mean, standard deviation [SD], 
median, interquartile range [IQR], frequency, and/or per-
cent) were calculated for patient demographics, smok-
ing history and responses to the investigator-developed 
questions. Descriptive statistics were also calculated for 
the 5 domains of the mCEQ, and for the SCAS questions 
in which responses of “Pleasant,” “Very Pleasant,” and 
“Extremely Pleasant” was collapsed into a single category. 
Continuous variables were described as mean ± SD, or 
median [25th percentile; 75th percentile]. Discrete vari-
ables were described as frequencies (%).
Analysis of variance (ANOVA) or the Kruskal–Wallis 
test, as appropriate based on distribution, was used to 
assess the associations between categorical variables of 
interest and (1) the 5 mCEQ domains and (2) the Total 
SCAS score. Categorical variables of interest included 
baseline age category (18–34, 35–44, 45+), residence 
type (rural, suburban or urban), age range when the 
participant began smoking (≤ 13  years, 14–15  years, 
16–17  years, 18+ years), number of years smoked 
(≤ 15  years, 16–25  years, 26–35  years, 36+  years), and 
number of times attempted quitting (< 5 times, 6–10 
times, 11+  times). When overall differences were 
observed, post-hoc tests (Tukey HSD and Dunn–Holm) 
were used to assess differences between pairs of groups 
and adjust for multiple comparisons. The two-sample 
t test or Wilcoxon rank-sum test, as appropriate, was 
used to assess the associations between binary vari-
ables of interest (gender and daily number of cigarettes 
smoked (≤ 20, 21+) and mCEQ domains and the SCAS 
Total score. The chi-square test or Fisher’s exact test, as 
appropriate based on expected cell counts, was used to 
assess the association between discrete variables of inter-
est and the above outcomes. All p values were two-sided 
with statistical significance evaluated at the 0.05 alpha 
level. Ninety-five percent confidence intervals (95% CIs) 
were computed to assess the precision of the obtained 
estimates. All analyses were performed using R Version 
3.3.1 (R Foundation for Statistical Computing, Vienna, 
Austria).
Results
Participant Characteristics and smoking history
Table  1 describes participants’ sociodemographic and 
smoking history characteristics.
Smokers typically make multiple quit attempts [36] as 
was true of almost half of our participants. The majority 
of participants began smoking before age 18, smoked for 
at least 16 years, and about half reported smoking more 
than 20 cigarettes per day. The vast majority of the sam-
ple identified as “White” with those aged 45–54 the most 
represented. There were slightly more females and most 
lived in suburbia or rural areas.
Investigator‑developed questions
Presence and quality of sensory experiences and cues using 
an e‑cigarette
Responses from ten investigator-developed questions 
indicated that the majority of participants experienced 
respiratory sensations when using their e-cigarettes and 
enjoyed the sensations (Table 2). The presence of sensa-
tions varied based on their location in the respiratory 
tract, with sensations in the throat being the most com-
mon and in the lungs the least. Enjoyment of sensa-
tions varied, with the tongue and throat being the most 
enjoyable.
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Importance of sensory experiences’ influence on cessation 
outcomes
Table  3 describes participants’ responses to the impor-
tance of sensations and the extent to which they believed 
these sensations contributed to their ability to quit smok-
ing. Participants were asked to rate on a 7-point Likert 
scale (Not at all (1) to extremely (7) the importance of 
the sensation of the vapor. The proportion of responses 
to the statement, “The feeling of the vapor when I used 
my e-cigarette is important to me,” was: not at all (5.03%), 
very little (5.66%), a little (5.03%), moderately (17.61%), a 
lot (18.87%), quite a lot (25.16%), and extremely (22.64%). 
Together, eighty-four percent of participants reported 
the sensation of the vapor as moderately to extremely 
important.
Participants were asked to rate on a 7-point Likert 
scale (Not at all (1) to extremely (7)) the extent to which 
sensations associated with e-cigarette use influenced 
cessation outcomes. The proportions of responses to 
the statement, “The feeling of the vapor when I use my 
e-cigarette contributed to my smoking cessation success,” 
were: not at all (3.18%), very little (1.91%), a little (3.82%), 
moderately, (7.01%), a lot (11.46%), quite a lot (20.38%), 
and extremely (52.23%). Together, ninety one percent of 
participants believed the sensations accompanying e-cig-
arette use contributed moderately to extremely to their 
smoking cessation success.
The Modified Cigarette Evaluation Questionnaire (mCEQ)
As can be seen in Table  4, mean scores on the five 
domains of the mCEQ based on the 7 point Likert scale 
1 (not at all) to 7 (extremely) indicate that participants 
reported high levels of satisfaction (mean of 19.7 out 
of a maximum of 21), enjoyment (mean of 5.6 out of a 
maximum of 7), and craving reductions (mean of 6.0 out 
of a maximum of 7); moderate levels of psychological 
Table 1 Participant characteristics and smoking history
Demographics n (%)
Gender
 Female 85 (55.6%)
 Male 58 (44.4%)
Age (in years)
 18–24 2 (1.30%)
 25–34 49 (31.8%)
 35–44 36 (23.4%)
 45–54 57 (37.0%)
 55–64 10 (6.49%)
Residence
 Urban 35 (22.9%)
 Suburban 66 (43.1%)




 No 4 (2.6%)
 African American
 Yes 2(1.3%)
 No 154 (98.7%)
 Asian American
 Yes 2(1.3%)
 No 154 (98.7%)
 American Indian
 Yes 10 (6.4%)
 No 146 (93.6%)
Smoking history n (%)
 Age started smoking
 ≤ 13 years 33 (21.4%)
 14–15 years 53 (34.4%)
 16–17 years 43 (27.9%)
 ≥ 18 years 25 (16.2%)
 Years smoked
 ≤ 15 years 46 (30.9%)
 16–25 years 37 (24.8%)
 26–35 years 40 (26.8%)
 ≥ 36 years 26 (17.4%)
 Cigarettes per day
 ≤ 20 72 (47.4%)
 ≥ 21 80 (52.6%)
 Number of previous quit attempts
 ≤ 5 times 75 (54.7%)
 6–10 times 34 (24.8%)
 ≥ 11 times 28 (20.4%)
Table 2 Respiratory tract sensations and  enjoyment 
reported during e-cigarette use
a Sensation: Investigator-developed questions: I feel the vapor in my throat 
when I use my e-cigarette; I feel the vapor on my tongue when I use my 
e-cigarette; I feel the vapor in my windpipe when I use my e-cigarette; I feel the 
vapor in my nose when I use my e-cigarette; I feel the vapor in my lungs when I 
use my e-cigarette
b Enjoys the Sensation: Investigator-developed questions: I enjoy the feeling of 
the vapor in my throat when I use my e-cigarette; I enjoy the feeling of the vapor 
on my tongue when I use my e-cigarette; I enjoy the feeling of the vapor in my 
windpipe when I use my e-cigarette; I enjoy the feeling of the vapor in my nose 









Throat 97 93%, 99% 95 90%, 98%
Tongue 94 89%, 97% 98 94%, 99%
Windpipe 75 67%, 81% 86 80%, 91%
Nose 72 64%, 79% 85 78%, 90%
Lungs 67 60%, 74% 82 75%, 87%
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reward (mean of 22.2 out of a maximum of 35); and low 
levels of aversion to e-cigarette use (mean of 2.4 out of a 
maximum of 14). In fact, ninety percent of participants 
reported no aversion to e-cigarette use with questions 
specifically asking about nausea and dizziness.
As can be seen in Table 5, scores on the vaping satis-
faction and enjoyment domains of the mCEQ varied 
significantly according to the age at which the partici-
pant began smoking (13  years or younger, 14–15  years, 
16–17  years or 18  years or older). ANOVA yielded dif-
ferences between the four age groups on the mCEQ 
Satisfaction domain (overall p = 0.013), and the post 
hoc Tukey HSD test indicated that the 16–17-year-old 
group (mean ± sd: 19.2 ± 1.97) had a significantly lower 
mCEQ Satisfaction score compared to the 13-year-old 
and younger group (mean ± sd: 20.4 ± 1.23), p = 0.015. 
The non-parametric Kruskal–Wallis test indicated an 
overall association between the age the participant began 
smoking and the mCEQ Enjoyment domain score (over-
all p = 0.017). Post hoc testing (Dunn–Holm) showed a 
significant difference in the median mCEQ Enjoyment 
score, between the 16–17-year-old group (Median [IQR] 
of 5.00 [4.00;6.00]) and both the 14–15-year-old group 
(Median [IQR] of 6.00 [5.00;7.00]) and the 13-year-old 
and younger group (Median [IQR] of 6.00 [5.00;7.00]), 
p = 0.026 and p = 0.047, respectively. In addition, enjoy-
ment of e-cigarette use differed according to years 
smoked (overall p = 0.038). After adjusting for multiple 
comparisons, there was a trend observed between those 
who smoked 26–35 years versus 36 or more years, with 
a p value of 0.061 for the pairwise comparison, suggest-
ing that the test might be underpowered to detect the 
difference.
The majority (96% [95% CI 89%, 97%]) of participants 
reported moderate to extreme reductions in nicotine 
craving with e-cigarette use as reflected in responses 
to the single item mCEQ question, “Does your e-ciga-
rette immediately reduce your cravings for nicotine?” 
[34] Women scored significantly higher on the Crav-
ing Reduction domain compared to men (Median of 
7.0 [6.00; 7.00] vs 6.0 [5.00; 7.00], p = 0.023). As seen in 
Table 4, there were no statistically significant associations 
observed between mCEQ domains and baseline age, 
type of residence, number of cigarettes smoked daily and 
number of quit attempts.
The smoking cue appeal survey (SCAS)
The experience of smoking cues with e-cigarette 
use was evaluated using the SCAS. As can be seen in 
Table  6, almost all participants (99% [95% CI 95%, 
100%]) reported a pleasant experience using their 
e-cigarettes. Pleasantness was especially attributed to 
a variety of sensory cues such as tasting, smelling and 
seeing the vapor and touching the device. As can be 
Table 3 Importance of sensory experiences’ influence on cessation outcomes
Statement Not at all (1) (%) Very 
little (2) 
(%)
A little (3) (%) Moderately 
(4) (%)




The feeling the vapor is important to me 
when I use my e-cigarette
5.03 5.66 5.03 17.61 18.87 25.16 22.64
The feeling of the vapor when I use my 
e-cigarette contributed to my smoking 
cessation success
3.18 1.91 3.82 7.01 11.46 20.38 52.23
Table 4 Mean and  median scores on  the  five domains 
of the mCEQ
a Smoking Satisfaction = average of mCEQ questions #1 (Was e-cigarette use 
satisfying?), #2 (Does the e-cigarettes taste good?), and #12 (Do you enjoy 
using your e-cigarette?); Psychological Reward = average of mCEQ questions #4 
(Does using your e-cigarette calm you down?), #5 (Does using your e-cigarette 
make you feel more awake?), #6 (Does using your e-cigarette make you feel less 
irritable?), #7 (Does using your e-cigarette help you concentrate?), and #8 (Does 
using your e-cigarette reduce your hunger for food?); Enjoyment of Respiratory 
Tract Sensation: mCEQ questions #3 (Do you enjoy the sensation in your throat 
and chest?); Craving Reduction: mCEQ question #11 (Does using your e-cigarette 
immediately reduce your craving for nicotine?); and Aversion = average of mCEQ 
questions #9 (Does using your e-cigarette make you dizzy?) and #10 (Does using 
your e-cigarette make you nauseous?). Questions on the mCEQ were adapted 
to refer to e-cigarettes and e-cigarette use. Vaping Satisfaction = average of 
mCEQ questions #1 (Was e-cigarette use satisfying?), #2 (Does the e-cigarettes 
taste good?), and #12 (Do you enjoy using your e-cigarette?); Psychological 
Reward = average of mCEQ questions #4 (Does using your e-cigarette calm 
you down?), #5 (Does using your e-cigarette make you feel more awake?), 
#6 (Does using your e-cigarette make you feel less irritable?), #7 (Does using 
your e-cigarette help you concentrate?), and #8 (Does using your e-cigarette 
reduce your hunger for food?); Enjoyment of Respiratory Tract Sensation: mCEQ 
questions #3 (Do you enjoy the sensation in your throat and chest?); Craving 
Reduction: mCEQ question #11 (Does using your e-cigarette immediately 
reduce your craving for nicotine?); and Aversion = average of mCEQ questions 
#9 (Does using your e-cigarette make you dizzy?) and #10 (Does using your 
e-cigarette make you nauseous?). Questions on the mCEQ were adapted to refer 
to e-cigarette use. Results were adapted to vaping rather than smoking.
Domaina Mean (SD) score Median [IQR] score N
Vaping satisfaction 19.7 (2.0) 21.0 [19.0; 21.0] 155
Psychological reward 22.2 (6.3) 22.0 [18.0; 26.5] 155
Enjoyment of respira-
tory tract sensations
5.6 (1.4) 6.0 [5.0; 7.0] 156
Craving reduction 6.0 (1.3) 6.0 [6.0; 7.0] 156
Aversion 2.4 (1.2) 2.0 [2.0; 2.0] 155
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seen in Table 7, the age of participants was significantly 
related to the extent to which they experienced sensory 
cues associated with e-cigarettes as pleasant (p = 0.01). 
A Tukey HSD post hoc test showed that 18–34  years 
had a lower mean SCAS total score (− 14.55 ± 5.45) 
indicating more perceived pleasantness compared to 
45+ years olds (− 11.54 ± 6.11), p = 0.012.
There were no statistically significant associations 
observed between SCAS scores and gender, age of ini-
tiation of smoking, years of smoking, type of residence, 
number of cigarettes smoked daily, and number of quit 
attempts.
Discussion
The goal of this study was to characterize the extent and 
quality of respiratory sensations and sensory-related 
smoking cues associated with e-cigarettes. Further, we 
examined the extent to which participants believed sen-
sory experiences accompanying e-cigarette use contrib-
uted to their cessation outcomes.
 In our study, all our participants substituted e-ciga-
rettes for CTC after trying and failing to quit CTC using 
a FDA approved cessation medication. Evidence suggests 
that substituting an e-cigarette for CTC may improve 
cessation outcomes, and in some cases substitution may 
Table 5 Association of  demographics and  smoking history and  domains of  the  modified cigarette evaluation 
questionnaire (mCEQ)
*Statistically significant differences (at p < 0.05) were found between gender and craving reduction (p = 0.023); ratings of vaping satisfaction and age participants 
began smoking (overall p = 0.013); ratings of enjoyment and age began smoking (overall p = 0.017); and ratings of enjoyment and years smoked (overall p = 0.038)
**Post hoc tests indicated that the 16–17 year-old group had significantly lower Satisfaction (p = 0.015) and Enjoyment (p = 0.047) scores compared to the 13-year-old 
and younger group. The 16–17-year-old group also had significantly lower Enjoyment scores compared to the 14–15 year-old group (p = 0.026). There was a trend for 
higher Enjoyment scores between those who have been smoking 26–35 years compared to those smoking 36 years or more (p = 0.061 after adjusting for multiple 
comparisons)




 Male 19.5 ± 1.94 22 (19.0; 25.2) 6.0 (5.0; 7.0) 6.0 (5.0; 7.0) 2.0 (2.0; 2.0)
 Female 19.8 ± 2.15 23 (18.0; 28) 6.0 (5.0; 7.0) 7.0 (6.0; 7.0)* 2.0 (2.0; 2.0)
Baseline age
 18–34 19.7 ± 2.01 23.0 (21.0; 26.5) 6.0 (5.0; 7.0) 7.0 (6.0; 7.0) 2.0 (2.0; 2.0)
 35–44 20.2 ± 1.33 21.0 (15.526.0) 6.0 (4.0; 7.0) 6.5 (5.75; 7.0) 2.0 (2.0; 2.0)
 45+ 19.5+/2.29 23.0 (18.0; 27.0) 6.0 (5.0; 7.0) 6.0 (5.0; 7.0) 2.0 (2.0; 2.0)
Residence type
 Rural 19.9 ± 1.93 22.5 (19.0; 26.0) 6.0 (5.0; 7.0) 6.0 (6.0; 7.0) 2.0 (2.0; 2.0)
 Suburban 19.7 ± 1.74 22.0 (17.2; 26.8) 6.0 (4.25; 7.0) 7.0 (5.25; 7.0) 2.0 (2.0; 2.0)
 Urban 19.3 ± 2.73 23.0 (19.0; 27.5) 6.0 (5.0; 7.0) 7.0 (4.50; 7.0) 2.0 (2.0; 2.0)
Age began smoking
 < 13 years 20.4 ± 1.23* 23.0 (20.0; 27.0) 6.0 (5.0; 7.0)** 7.0 (6.0; 7.0) 2.0 (2.0; 2.0)
 14–15 years *20.1 ± 1.26 22.0 (18.0; 27.0) 6.0 (5.0; 7.0) 7.0 (6.0; 7.0) 2.0 (2.0; 2.0)
 16–17 years 19.2+/1.97** 22.0 (18.0; 26.0) 5.0 (4.0; 6.0)** 6.0 (6.0; 7.0) 2.0 (2.0; 2.0)
 18+ years 19.5 ± 2.52 24.0 (20.0; 26.0) 5.0 (5.0; 7.0) 6.0 (5.0; 7.0) 2.0 (2.0; 2.0)
Years smoked
 ≤ 15 years 19.6 ± 2.06 23.0 (21.0; 27.8) 6.0 (5.0; 7.0) * 6.0 (6.0; 7.0) 2.0 (2.0; 2.0)
 16–25 years 19.9 ± 1.82 22.0 (17.0; 26.0) 6.0 (4.0; 7.0) 7.0 (5.0; 7.0) 2.0 (2.0; 2.0)
 26–35 years 20.2 ± 1.2 25.0 (18.0; 27.5) 6.5 (5.8; 7.0) 7.0 (6.0; 7.0) 2.0 (2.0; 2.0)
 36+ years 19.5 ± 1.92 20.5 (17.2; 26.0) 5.0 (5.0; 6.00) 6.0 (5.25; 7.0) 2.0 (2.0; 2.0)
Daily number of cigarettes smoked
 20 or < 19.6 ± 1.9 22.5 (18.0; 26.2) 6.0 (4.0; 7.0) 6.0 (5.75; 7.0) 2.0 (2.0; 2.0)
 21 or > 20.0 ± 1.6 22.0 (18.0; 27.0) 6.0 (5.0; 7.0) 7.0 (6.0; 7.0) 2.0 (2.0; 2.0)
Quit attempts
 < 5 times 19.6 ± 1.89 22.0 (17.5; 26.0) 6.0 (5.0; 6.50) 6.0 (5.0; 7.0) 2.0 (2.0; 2.0)
 6–10 times 20.0 ± 1.63 25.0 (20.0; 27.0) 6.0 (5.0; 7.0) 7.0 (6.0; 7.0) 2.0 (2.0; 2.0)
 11+ times 20.1 ± 1.71 23.0 (20.5; 27.5) 7.0 (5.0; 7.0) 7.0 (6.0; 7.0) 2.0 (2.0; 2.0)
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yield a more robust cessation outcome compared to 
approved cessation medications. Hajeck and colleagues 
[37] compared 1  year abstinence rates (N = 886) among 
an e-cigarette group and a nicotine replacement group 
and reported 18.0% and 9.9% rates of cessation, respec-
tively. Six month CO-verified continuous abstinence rates 
combining a nicotine containing e-cigarette with a nico-
tine patch (7%, n = 35) was superior to a non-nicotine 
containing e-cigarette and nicotine patch (4%, n = 20) 
group, and a nicotine patch alone (2%, n = 3) [38]. Sev-
eral comprehensive systematic reviews concluded that 
e-cigarettes may be effective substitutes to help smokers 
quit or reduce smoking, yet these findings are inconclu-
sive due to the low quality of the studies or small sample 
sizes [39–41].
The majority of participants in our study rated the 
sensations from the vapor as important and attributed 
the sensory aspect of e-cigarette use to their success at 
quitting CTC. These findings suggest the possibility that 
sensory experiences may be missing links in the effective-
ness of current cessation medications. In contrast to the 
sensory stimulation with e-cigarette use, approved ces-
sation medications focus exclusively on interrupting the 
nicotine addiction. Except for the nicotine inhaler, which 
mimics some of the hand-to-mouth sensory-motor cues 
of smoking [42], and the nasal spray that may induce 
some of the respiratory sensations of smoking, none of 
these medications are designed specifically to replicate 
the sensory experiences of smoking. Further, mouth, 
throat, and nose irritations are reported by users of the 
inhaler and spray [43].
E-cigarettes are designed to simulate the smoking 
experience, similar to the cigarette substitutes intro-
duced by Rose and others [15, 16]. Aerosol from a nico-
tine containing solution is inhaled, and many e-cigarettes 
have the same features as a traditional cigarette such as 
shape, a filter, and red or orange glowing tip [44] and are 
associated with smoking-specific cues such as visible 
smoke, which is actually vapor [25]. Better understanding 
e-cigarette users’ sensory experiences is vital to consid-
ering novel approaches or improving existing cessation 
interventions.
Regarding the sensory experiences of e-cigarette users 
in our study, participants endorsed satisfying and enjoy-
able sensations throughout the respiratory tract (i.e., 
throat, tongue, windpipe, nose and lungs). These find-
ings are consistent with other research. In Dawkins and 
colleagues’ online survey of e-cigarette users [23], par-
ticipants described sensations accompanying e-cigarette 
Table 6 Smoking Cue Appeal Survey (SCAS): Sensory Cues 
attributed to “Pleasantness”
*Cue = the proportion of respondents who indicated use of their e-cigarette 
was pleasant, very pleasant, or extremely pleasant. NOTE: Questions on the 
SCASwere adapted to refer to e-cigarettes and e-cigarette use.
Cuea Proportion reporting 
pleasantness (%)
95% CI
Tasting the Vapor 98 94%, 99%
Smelling the vapor 88 82%, 93%
Touching the Device 78 71%, 84%
Seeing the Vapor 76 68%, 72%
Overall experience 99 95%, 100%
Smell of another’s use 85 78%, 90%
Taste of another’s use 35 28%, 44%
Sight of another’s use 50 42%, 58%
Table 7 Association of demographics and smoking history 
and total SCAS scores
*ANOVA: p < 0.05.
**Post hoc tests indicated that those 18–34 years had a lower mean SCAS total 
score (− 14.55 ± 5.45) indicating more perceived pleasantness compared to 45+ 
years olds (− 11.54 ± 6.11), p = 0.012.





 Male − 12.82 ± 4.89 p = 0.506
 Female − 13.43 ± 6.31
Baseline age
 18–34 − 14.55 ± 5.45 *p = 0.01
 35–44 − 14.00 ± 4.61 **p = 0.012
 45+ − 11.54 ± 6.11
Residence type
 Rural 2.00 (2.00; 2.00) p = 0.470
 Suburban 2.00 (2.00; 2.00)
 Urban 2.00 (2.00; 2.00)
Age began smoking
 < 13 years − 14.00 (− 17.00; − 10.00) 0.384
 14–15 years − 14.00 (− 19.00; − 9.00)
 16–17 years − 12.00 (− 15.00; − 9.00)
 18+ years − 13.00 (− 18.00; − 7.00)
Years smoked
 ≤ 15 years − 14.33 ± 5.24 0.070
 16−25 years − 14.05 ± 5.54
 26–35 years − 13.32 ± 5.78
 36+ years − 10.83 ± 5.06
Daily number of cigarettes smoked
 20 or < − 13.34 ± 5.35 0.859
 21 or > − 13.18 ± 5.68
Quit attempts
 < 5 times − 13.01 ± 5.23 0.764
 6–10 times − 13.79 ± 5.78
 11+ times − 12.96 ± 5.73
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use as “satisfying.” In Berg and colleagues’ online survey 
of e-cigarette users [24], participants said the sensation 
of blowing out vapor and the flavors reinforced cessa-
tion beyond nicotine replacement alone. In our study, the 
greatest enjoyment was experienced on the tongue and in 
the throat. This finding is consistent with other research. 
In Etter and colleagues’ study [26], participants attrib-
uted smoking cessation success to the extent of “throat 
hit” experienced while using their e-cigarettes. In a study 
conducted by Barbeau and colleagues [25] e-cigarette 
using participants in focus groups also reported enjoying 
the feeling of “throat hit.”
Enjoyment varied by age of initiation of smoking. We 
found that those who began smoking at a younger age 
had greater enjoyment and satisfaction from e-cigarettes. 
There was a statistically significant difference between 
those who began smoking between 16–17  years of age 
and both those who began smoking at 14–15  years 
old and those who began smoking at 13 years of age or 
younger. In our sample, enjoyment was significantly 
related to smoking tenure. After adjusting for multiple 
comparisons, those who smoked 26–35  years tended to 
have more e-cigarette enjoyment than those who had 
smoked 36 or more years (p value of 0.061 for the pair-
wise comparison), suggesting that the test might be 
underpowered to detect the difference. The reason less 
established smokers may experience more enjoyment 
is not addressed specifically in the literature. It may be 
that it is more difficult for entrenched smokers to find 
enjoyment using the alternative e-cigarette because the 
enjoyment experienced during smoking has been firmly 
established. In fact, in a survey of cigarette smokers, 
the main reason for not transitioning to an e-cigarette 
included enjoyment of traditional cigarette smoking [45].
Enjoyment and satisfaction may influence use of 
e-cigarettes and CTC [45–49] therefore both are criti-
cal to consider. In fact, among a sample of college stu-
dents between the ages of 18 and 23  years, enjoyment 
surpassed all reasons for daily and non-daily e-cigarette 
use, including quitting or reducing smoking and decreas-
ing craving [47]. In a nationally representative sample of 
adolescents and young adults in the United States, Barker 
and colleagues found a robust association between enjoy-
ment of e-cigarette use and intention to use e-cigarettes. 
According to the findings from the 2016 ITC Four 
Country Smoking and Vaping wave 1 (4CV1) surveys 
conducted in the United States, England, Canada, and 
Australia [50], the greatest motivation for e-cigarette use 
among ex-cigarette smokers was enjoyment. Therefore, 
understanding more about how length of smoking ten-
ure and age of smoking initiation may impact enjoyment 
and satisfaction of e-cigarettes is important to address in 
future research.
Varied enjoyment/satisfaction may be explained 
by differences in the nicotine strength of users’ origi-
nal CTC compared to the strength of the e-cigarette, 
participants’ levels of nicotine dependence, types of 
devices, and flavors. In our study, enjoyment and sat-
isfaction were not correlated with number of cigarettes 
smoked per day or number of quit attempts, both asso-
ciated with greater nicotine dependence [1, 51]. Fur-
ther, there was no significant difference in enjoyment 
of e-cigarettes between genders. This could be related 
to the development of newer generation devices, 
increased product acceptability and accessibility, as 
compared to earlier research where males scored higher 
than females on attributes of enjoyment to maintain 
e-cigarette use [52], while using first (10%) and second 
(61%) generation devices.
Perhaps enjoyment may influence e-cigarette use dif-
ferently based on gender. It is well established that gender 
differences exist with cigarette smoking behavior [52] and 
product choice [53]. However, research focused on gen-
der influences of e-cigarette use behavior are still being 
established and is an area in need of further research [52].
Participants endorsed sensory cues accompanying 
e-cigarette use (e.g. tasting, smelling, seeing the vapor 
and touching the device). “Pleasantness” was attributed 
to these cues. Similar findings from a qualitative study 
attributed “biobehavioral feedback” to the efficacy of 
an e-cigarette for cessation. Participants in this study 
emphasized the sensory cues of e-cigarette use, such as 
seeing the vapor cloud when they exhaled as influencers 
for cessation [25]. In our study, 18–34-year-olds expe-
rienced greater “pleasantness” compared to those 45 or 
more years.
Moderate to extreme reductions in nicotine craving 
were reported by the majority (94%) of our sample.
Craving reductions with e-cigarette use are docu-
mented in the literature. A randomized controlled trial 
demonstrated a reduction in cigarette craving that was 
of the same magnitude as when a cigarette was smoked 
when using an e-cigarette after 4  h of abstinence from 
smoking [33]. Craving reductions have been documented 
in other studies [23, 54, 55]. Findings of a Web-based sur-
vey of 1672 e-cigarette users demonstrated an associa-
tion between higher levels of nicotine in the e-cigarette, 
stronger “throat hit,” increased relief of cravings, smoking 
cessation, and “satisfaction” when using the e-cigarette 
[26]. Women experienced significantly greater crav-
ing reductions in our study. This is consistent with find-
ings from an on-line survey of e-cigarette users in which 
females were more likely to agree that the e-cigarette 
dramatically reduced cravings for nicotine [23]. Expec-
tations may influence gender differences in experiences 
with e-cigarette use. In an online survey, women were 
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significantly more likely to maintain e-cigarette use for 
the purpose of dealing with stress or to control moods 
[56].
Conclusions
In conclusion, the results of our study suggest the impor-
tance of sensory experiences when switching from CTC 
to a cessation aide. In our sample, sensory experiences 
influenced cessation outcomes. This finding underscores 
the importance of considering the sensory impact of 
smoking when designing interventions for cessation. It 
is conceivable that the absence of sensory stimulation 
may be a factor in the limitations of approved cessation 
medications to achieve robust and sustained cessation 
outcomes.
Our findings do not specifically support an e-cigarette 
as a substitute for CTC. The safety profile of e-cigarettes 
is still being evaluated and there exists a global debate 
about the appropriateness of promoting e-cigarettes 
as tools to help smokers quit. Rather, we urge fellow 
researchers and clinicians reflect on the seminal works of 
Cain [15, 17]. It is best to think seriously about the pre-
cision to which TI scientists design cigarettes to ingrain 
smoking behavior by engineering the perfect sensory 
influencing and nicotine supplying device. Is it possible 
that our cessation failure outcomes are still estimated to 
be as high as 50% 1-year postquit [8–12], because our 
approved cessation medications address only the nicotine 
addiction but not the sensory impacts of smoking? How 
would the lives of 1.1 billion smokers worldwide [13] 
be improved if our cessation interventions matched the 
design of the CTC by addressing both the sensory impact 
of smoking and the nicotine addiction? Current e-ciga-
rettes already allow consumers to tailor their experience 
right down to an individual level, and so it is perhaps the 
concept of ’recognising and permitting pleasure’ as an 
adjunct to nicotine replacement which must be adopted 
in the first place in order for the intervention to succeed.
At present, to our knowledge, e-cigarettes are the most 
viable CTC substitutes that provide the sensory experi-
ence and cues that appear to be important for smoking 
cessation. It is for this reason that we encourage further 
research of the e-cigarette for safety, substitution, and 
sensory impact. Further, it will be important for future 
research to determine which other types of devices might 
be helpful to create sensory cues and experiences that 
might help smokers quit.
Limitations should be considered when interpreting 
our results. Survey responses from our small non-repre-
sentative sample may be biased based on affiliation. Par-
ticipants were recruited through CASAA, an advocacy 
group for electronic nicotine devices. Further, the sample 
size was limited to 156 based on funding. Additionally, 
the sample excludes those who are less likely to utilize 
social media, electronics or the web. A standard 6-month 
cessation criterion, [57] rather than a 3-month cessation 
criterion for eligibility would enhance ability to compare 
results with other studies. No data were collected on the 
frequency of e-cigarette use, which may influence CTC 
cessation outcomes [58]. Nor were data collected regard-
ing e-cigarette brands, nicotine content, or flavors, all 
of which have the potential to influence sensory experi-
ences. In fact, by the year 2014, there were 466 e-cigarette 
brands and 7764 unique flavors of e-cigarettes identified 
by an internet search [59, 60]. A review of 16 brands of 
e-cigarettes found variations in levels of nicotine in the 
vapor from 0.5 to 15.4 mg [49].
Implications for future research include compar-
ing sensory experiences and cessation outcomes among 
stratified samples of e-cigarette users of varying nicotine 
strengths, brands, and flavors, and including patterns 
of e-cigarette use as variables of interest. Adding a con-
trol group of “dual users” of both CTCs and e-cigarettes 
versus exclusive e-cigarette users would be of interest to 
determine if responses to the questionnaire are different 
between exclusive e-cigarette users (successful sustained 
abstinence from tobacco cigarettes) versus dual (quit fail-
ures) users.
In spite of these limitations, study findings add valu-
able insights. While the sensory influences of smoking 
behavior are well understood by current and seminal 
research, none of the approved cessation medications are 
designed with the sensory reinforcers of smoking behav-
ior in mind. Our results suggest the potential importance 
of including such sensory influences in CTC cessation 
interventions.
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